Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Philip W. Connelly
ResearcherPublications, citations & collaboration network
Philip W. Connelly is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 369 works, 18,175 citations, an h-index of 73 and an i10-index of 251.
369
Works
18,175
Citations
73
h-index
251
i10-index
How has Philip W. Connelly's publication output changed over time?
ScholarIQpublication output · 1993–2019
Output grew0% over the shown period — from 1 works in 1993 to 1 in 2019.
1
1
1
4
1
1
2
1
19931996200120022003200520082019
What are the most-cited papers on Philip W. Connelly?
ScholarIQmost cited works
A major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Myron I. Cybulsky, Kaeko Iiyama, Hongmei Li, Su-Ning Zhu, Mian Chen, Motoi Iiyama, Vannessa Davis, José-Carlos Gutierrez-Ramos, Philip W. Connelly, David S. Milstone
S114430552. 20011,211 CitationsOPEN ACCESS
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins
Michael I. Mackness, Bharti Mackness, Paul N. Durrington, Philip W. Connelly, Robert A. Hegele
S203964698. 1996447 Citations
Dose Response of Almonds on Coronary Heart Disease Risk Factors: Blood Lipids, Oxidized Low-Density Lipoproteins, Lipoprotein(a), Homocysteine, and Pulmonary Nitric Oxide
David J.A. Jenkins, Cyril W.C. Kendall, Augustine Marchie, Tina Parker, Philip W. Connelly, Wei Qian, James S. J. Haight, Dorothea Faulkner, Edward Vidgen, Karen G. Lapsley, Gene A. Spiller
Circulation. 2002378 Citations
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C. David Mazer, Gregory M. T. Hare, Philip W. Connelly, Richard E. Gilbert, Nadine Shehata, Adrian Quan, Hwee Teoh, Lawrence A. Leiter, Bernard Zinman, Peter Jüni, Fei Zuo, Nikhil Mistry, Kevin E. Thorpe, Ronald Goldenberg, Andrew T. Yan, Kim A. Connelly, Subodh Verma
Circulation. 2019363 Citations
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein
Thomas M.S. Wolever, Alison L. Gibbs, Christine C. Mehling, Jean‐Louis Chiasson, Philip W. Connelly, Robert G. Josse, Lawrence A. Leiter, Pierre Maheux, Rémi Rabasa‐Lhoret, N. W. Rodger, Edmond A. Ryan
American Journal of Clinical Nutrition. 2008335 CitationsOPEN ACCESS
Related on ScholarIQ
St. Michael's Hospital
Institution
A major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Paper
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins
Paper
Dose Response of Almonds on Coronary Heart Disease Risk Factors: Blood Lipids, Oxidized Low-Density Lipoproteins, Lipoprotein(a), Homocysteine, and Pulmonary Nitric Oxide
Paper
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Paper
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein
Paper